Tagged with Biosimilar

Taiwan The co-founder and president of Mycenax Biotech, Dr. Karen Wen details the key lessons learned from the development of their first in-house product TuNEX® and how they have been applied to their second flagship product LusiNEX (tocilizumab). She also details the company’s transition from a platform-driven service provider to a…

Pharma Sandra Sánchez, General Manager at PROBIOMED, explains the crucial role that biosimilars will play in the future healthcare system as well as the importance of complying with COFEPRIS’ regulations to expand PROBIOMED’s business within the region. Last time we met with you, you explained that PROBIOMED was following a three…

Pharma MD Natascha Schill discusses the growing importance and commitment that Biogen has to Switzerland, including a USD one billion investment in new facilities and the creation of 400 jobs in the upcoming years; investing in the local workforce to support the company’s growth. The headline-making news at the moment is…

Pharma Michaela Hrdlickova of Biogen elaborates on how it is the industry’s responsibility to educate all stakeholders within the Czech Republic in order to embed a health consciousness in every individual and discusses the unique referencing methods applied in the country and their resulting challenges for both industry and patient. When…

Pharma Biotest France’s Olivier Samama discusses their recent re-entry into France, their focus on homecare treatment, and their expertise in fractionation and plasma derived products. What are the objectives and goals you have been given by Dr Bernhard Ehmer and what exactly has happened in building this affiliate these last two…

Pharma Mr Kimelfeld and Ms Labat run us through the exceptional history of Lyon and the region in the life sciences field, how Lyon is considered to be the birthplace of bio industries in France, and why life sciences will remain an economic driving force of the local economy. Could you…

Pharma The executive director of the Česká asociace farmaceutických firem, the Czech Republic’s generic pharmaceutical association, elaborates on the code of ethics recently implemented and followed by all its members, which exceed the standards set in current legislation. Furthermore, he explains the implications for the industry of the ongoing EU-level discussions…

Pharma Teva Czech Republic & Slovakia GM Juan Carlos Conde describes how the Czech Republic hosts Teva’s third largest manufacturing site within Europe and the recent implementation of a more efficient cluster organization covering the Czech and Slovakian markets. You became general manager of Teva Pharmaceuticals Czech Republic & Slovakia eight…

Pharma Vojtěch Mészáros, Executive Director of Egis Praha, speaks about his background in the industry, his drive to promote biosimilar products, and how the company maneuvers around the growing price pressures in the market.  You hold an impressive profile in the pharmaceutical industry. Please introduce your background and leadership to our…

Pharma Ten years after his first interview with Focus Reports, Wafik Bardissi discusses Minapharm’s position as the leading biosimilar manufacturer in the Middle East. Has Egypt taken steps to incentivize the development or registration of biosimilar products? At present, more attention is required in Egypt to promote biosimilar development or encourage the registration of…

Pharma Massimo Visentin, Country Leader for Pfizer Italy, discusses the company’s remarkable success in 2015, his hopes and ambitions for the new year, and the need of the industry and Pfizer specifically to engage the government in the development of a more sustainable healthcare system. To start off, we are approaching…

pharma The managing director of Adcock Ingram’s prescription business, Ashley Pearce highlights the division’s strategic placement within the group’s overall activities, and how he plans on leveraging partnerships with various multinationals, expand into biosimilars and grow the generics business into a market leading position. Adcock Ingram has undergone several strategic changes…